 |
市場調査レポート
商品コード
1463305
免疫グロブリンの世界市場規模、シェア、成長分析、タイプ別、用途別 - 産業予測、2024～2031年Global Immunoglobulin Market Size, Share, Growth Analysis, By Type(Immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG)), By Application(Primary immunodeficiency diseases, autoimmune disorders) - Industry Forecast 2024-2031 |
||||||
| 免疫グロブリンの世界市場規模、シェア、成長分析、タイプ別、用途別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の免疫グロブリンの市場規模は、2022年に150億5,000万米ドルとなり、2023年の163億9,000万米ドルから、2031年までには324億2,000万米ドルに成長し、予測期間中（2024～2031年）のCAGRは8.90%で成長する見通しです。
世界の免疫グロブリン市場の大幅な成長は、免疫疾患の罹患率の上昇、診断と治療の進歩、支持的な規制政策、ヘルスケア支出の増加など、さまざまな要因によって推進されています。さらに、現在進行中の技術革新と研究投資が、免疫グロブリン療法の有効性と質を高めています。アジア太平洋やラテンアメリカをはじめとする新興市場への進出は、市場参入企業にとって有望な展望となります。これらの動向は、免疫グロブリン市場の良好な見通しを裏付けるものであり、利害関係者が技術革新を優先し、生産能力を拡大し、戦略的な市場浸透アプローチを採用することで、免疫グロブリン療法の需要拡大に対応することの重要性を強調するものです。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
免疫グロブリンの世界市場：タイプ別
- 市場概要
- 免疫グロブリン（IVIG）・皮下免疫グロブリン（SCIG）
免疫グロブリンの世界市場：用途別
- 市場概要
- 原発性免疫不全症
- 自己免疫疾患
- 感染症
- 低ガンマグロブリン血症
- 神経学的障害
- その他
免疫グロブリンの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- CSL Behring（Australia）
- Grifols（Spain）
- Takeda Pharmaceutical Company Limited（Japan）
- Octapharma AG（Switzerland）
- Kedrion Biopharma（Italy）
- Shire（Ireland）
- Biotest AG（Germany）
- China Biologic Products Holdings, Inc.（China）
- Sanquin（Netherlands）
- LFB Group（France）
- Bio Products Laboratory（UK）
- ADMA Biologics, Inc.（USA）
- GC Pharma（South Korea）
- Bharat Serums and Vaccines Ltd.（India）
- Shanghai RAAS Blood Products Co., Ltd.（China）
- Grifols Biologicals Inc.（USA）
- BPL Plasma, Inc.（USA）
- Green Cross Corporation（South Korea）
- Beijing Tiantan Biological Products Corporation Limited（China）
- Emergent BioSolutions（USA）
Global Immunoglobulin Market size was valued at USD 15.05 billion in 2022 and is poised to grow from USD 16.39 billion in 2023 to USD 32.42 billion by 2031, growing at a CAGR of 8.90% during the forecast period (2024-2031).
The substantial growth of the global Immunoglobulin market is propelled by various factors including the rising incidence of immunological disorders, advancements in diagnosis and treatment, supportive regulatory policies, and increased healthcare spending. Furthermore, ongoing technological innovations and research investments are bolstering the effectiveness and quality of Immunoglobulin therapies. Expanding into emerging markets, notably in Asia-Pacific and Latin America, offers promising prospects for industry participants. These trends underscore a favorable outlook for the Immunoglobulin market, emphasizing the importance for stakeholders to prioritize innovation, expand capacities, and adopt strategic market penetration approaches to cater to the growing demand for Immunoglobulin therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunoglobulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Immunoglobulin Market Segmental Analysis
The global immunoglobulin market is segmented by product type, application, and region. Based on type, the market can be segmented into immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG). Based on application, the market is segmented into primary immunodeficiency diseases, autoimmune disorders, infectious diseases, hypogammaglobulinemia, neurological disorders, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Immunoglobulin Market
One significant factor propelling the global Immunoglobulin market is the escalating prevalence of immunological disorders, encompassing primary immunodeficiency diseases, autoimmune disorders, and infectious diseases, for which Immunoglobulins play a pivotal role in treatment. This heightened demand for Immunoglobulin therapies stems from the growing occurrence of such disorders, bolstered by enhanced diagnostic capabilities and heightened awareness. Factors like genetic predisposition, environmental influences, and shifts in lifestyle patterns contribute to the increasing prevalence of immunological disorders worldwide. Furthermore, the market growth is buoyed by advancements in healthcare infrastructure, expanded access to healthcare services, and a rise in healthcare expenditure.
Restraints in the Global Immunoglobulin Market
A significant impediment in the global Immunoglobulin market stems from the elevated expenses associated with Immunoglobulin therapies. The intricate and costly production, purification, and storage processes involved in manufacturing Immunoglobulins contribute to high production costs, consequently influencing the pricing of Immunoglobulin products and rendering them relatively costly for patients and healthcare systems alike. This challenge is particularly pronounced in developing nations with limited healthcare budgets and financial constraints on affordability. Additionally, issues surrounding reimbursement and insurance coverage further exacerbate the financial burden on patients. Vital initiatives aimed at diminishing production costs, fostering market competition, and enhancing accessibility to economical Immunoglobulin therapies are imperative to mitigate this restraint and ensure widespread patient access to these crucial life-saving treatments.
Market Trends of the Global Immunoglobulin Market
One significant trend in the global Immunoglobulin market is the escalating uptake of intravenous immunoglobulin (IVIG) therapy, which entails administering Immunoglobulin intravenously to patients with immunodeficiency disorders, autoimmune diseases, and certain neurological conditions. The surge in demand for IVIG therapy is fueled by its efficacy in treating diverse medical conditions and the widening awareness of its benefits among both healthcare providers and patients. Factors such as advancements in production methods, enhanced product safety, and expanded indications for IVIG therapy are propelling its adoption. Moreover, the rising prevalence of immunological disorders and the growing geriatric population are further driving the increasing demand for Immunoglobulin products and IVIG therapy.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Immunoglobulin Market by Type
- Market Overview
- Immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG)
Global Immunoglobulin Market by Application
- Market Overview
- Primary immunodeficiency diseases
- autoimmune disorders
- infectious diseases
- hypogammaglobulinemia
- neurological disorders
- and others
Global Immunoglobulin Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion Biopharma (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biotest AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- China Biologic Products Holdings, Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanquin (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LFB Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio Products Laboratory (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ADMA Biologics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GC Pharma (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bharat Serums and Vaccines Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai RAAS Blood Products Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols Biologicals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BPL Plasma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Green Cross Corporation (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beijing Tiantan Biological Products Corporation Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
